BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $40
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $50
Spyre Therapeutics Analyst Ratings
Wedbush Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $45
Analysts' Top Healthcare Picks: PMV Pharmaceuticals (PMVP), Spyre Therapeutics (SYRE)
TD Cowen Remains a Buy on Spyre Therapeutics (SYRE)
Spyre Therapeutics Analyst Ratings
Spyre Therapeutics Analyst Ratings
Buy Rating Affirmed: Spyre Therapeutics' Promising Pipeline and Expert Team Drive Positive Outlook
Spyre Therapeutics Analyst Ratings
BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $40
Spyre Therapeutics (SYRE.US) was first covered by Baird, which gave it an superior market rating and a target price of $50.00.
Spyre Therapeutics Analyst Ratings
Buy Rating Affirmed for Spyre Therapeutics on Promising MAb Dosing and Market Positioning
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating
Spyre Therapeutics Analyst Ratings
Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $54
Strong Buy Rating for Spyre Therapeutics Based on Promising SPY001 Data and Financial Position
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Alnylam Pharma (ALNY) and Spyre Therapeutics (SYRE)
Spyre Therapeutics Analyst Ratings